.svg){kind=icon}
.svg){kind=logo}
Moxidectin for scabies
Towards a simplified scabies treatment. Clinical development of a new single-dose oral treatment that has the potential to enhance patient compliance, alleviate suffering, and contribute to reducing the prevalence and transmission of scabies.
Towards a simplified scabies treatment. Clinical development of a new single-dose oral treatment that has the potential to enhance patient compliance, alleviate suffering, and contribute to reducing the prevalence and transmission of scabies.
Medicines Development for Global Health acknowledges the sovereignty of the Peoples of the Boon Warrung/Woj Wurrung clan(s) of the Kulin nation of the land on which MDGH’s headquarters stand, and we pay our respects to their ancestors and Elders. We are here to achieve greater equity of access to good health globally, through the development of medicines for the treatment of neglected diseases, whilst respecting the right to self-determination of First Peoples everywhere.
Medicines Development for Global Health Limited.
Level 1, 18 Kavanagh Street Southbank Victoria 3006 Australia.
ABN: 79 116 977 523
